Matthew Schipper

Matthew Schipper, PhD

Director of Division of Biostatistics and Bioinformatics

School of Public Health
M2531 SPH II
1415 Washington Heights
Ann Arbor, MI 48109



Dr. Schipper has broad interest and expertise in Cancer Biostatistics. Specific areas of interest include predictive risk modeling, utility approaches in setting of competing outcomes, use of biomarkers to individualize and adapt cancer treatment and early phase oncology study design. He has collaborated with medical researchers in a wide variety of therapeutic areas with a focus on oncology, biomarkers and early phase clinical trials. He has authored or co-authored more than 130 papers published in peer-reviewed journals. 

Optimal Dose Selection: I have developed a utility based approach to optimal treatment dose selection based on statistical models for competing efficacy and toxicity outcomes. This approach is the basis for the individualized treatment in a current Phase II trial, and we are studying extensions to dynamic treatment regimes to allow for adaptation of treatment based on mid-treatment imaging or biomarkers.

Development and Application of Statistical Methods for Personalized Medicine: We are developing data driven approaches to identify a subgroup of patients who benefit from (or are harmed by) a treatment in the context of a negative randomized trial or observational study. Another area of my work has been directed towards personalizing treatment recommendations in prostate cancer. National guidelines recommend certain treatments (ADT for intermediate risk patients or active surveillance for low risk patients) for large populations of men with prostate cancer. We are working to personalize these  recommendations by incorporating additional information such as baseline clinical factors, genomic information on a patient's risk of dying of their prostate cancer and risk factors for non-cancer death.

Early Phase Oncology Study Design: I am currently working with other faculty and students on an extension of the Continual Reassessment Method to the setting of uncertain toxicity assessment. I have also studied the role of Dose Expansion Cohorts in early phase trial design and proposed statistically efficient designs that incorporate expansion cohorts.

Areas of Interest

  • Use of biomarkers to individualize treatment 
  • Early phase oncology study design 


  • PhD, University of Michigan, 2006


  • U064207: Assessing the impact of local and distant progression on overall survival: a meta-analysis. University of Michigan. Matthew Schipper, PI. 09/2018-12/2020. $60,000
  • 5 R01 CA240991-05: Determining the clinical impact of gene expression testing in localized prostate cancer NIHDHHS-US- 19-PAF00899. Co-I with Effort (Principal Investigator: Morgan, Todd;Spratt, Daniel). 09/2019-08/2024. $3,733,079 ($617,917)
  • 5 R01 EB022075-04: Imaging and Dosimetry of Yttrium-90 for Personalized Cancer Treatment NIH-DHHS-US- 16-PAF04955. Co-I with Effort (Principal Investigator: Dewaraja, Yuni Kamalika). 09/2016-09/2021. $1,842,344 ($461,991)
  • The Michigan Radiation Oncology Quality Consortium. Blue Cross Blue Shield of Michigan. Co-I with Effort (Principal Investigator: Lori Pierce). 02/2011-01/2050. $1,135,000 ($1,135,000)
  • 5 U01 CA216449-05: Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response NIHDHHS-US- 16-PAF07735. Co-I with Effort (Principal Investigator: Lawrence, Theodore S). 04/2017-03/2022. $2,905,890 ($578,379)
  • 5 P30 CA046592-33: Cancer Center Support Grant 2018-2023 NIH-DHHS-US- 17-PAF00945; 11-PAF03755; 11-PAF04124; 17-PAF05471. Co-I with Effort (Principal Investigator: Fearon, Eric R). 06/1997-05/2023. $29,985,989 ($7,556,288)
  • 5 R01 CA240515-05: Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer NIH-DHHS-US- 19-PAF08006. Co-I with Effort (Principal Investigator: Morgan, Meredith A). 03/2020-02/2025. $2,262,246
  • 5 R01 CA233487-05: Optimal Decision Making in Radiotherapy Using Panomics Analytics NIH-DHHS-US- 19-PAF02478. Co-I with Effort (Principal Investigator: El Naqa, Issam). 05/2024. ($451,307)
  • 3 P30 CA046592-30S3: Access to Experimental Therapeutics Clinical Trials Network (ETCTN) Agents at Univ of Michigan Site NIH-DHHS-US- 11-PAF03755; 11-PAF04124; 18-PAF00871; 17-PAF00945; 17-PAF05471; 20-PAF01501. Co-I with Effort (Principal Investigator: Eric R Fearon). 09/2011-05/2023. $37,331,617

Published Articles or Reviews

Selected from over 100 publications

  • Schipper MJ, Taylor JMG, TenHaken R, Matuzak M, Kong F and Lawrence TS. Personalized dose selection in Radiation Therapy using statistical models for toxicity and efficacy with dose and biomarkers as covariates. Stat Med, 33(30): 5330-9, 2014.
  • Boonstra PS, Shen J, Taylor JM, Braun TM, Griffith KA, Daignault S, Kalemkerian GP, Lawrence TS, Schipper MJ: A statistical evaluation of dose expansion cohorts in phase I clinical trials. J Natl Cancer Inst, 107(3): pii: dju429, 2015. PM25710960
  • Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M: Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J ClinOncol, 34(5): 452-9, 2016. PM26628466/PMC48720  
  • Dess R, Sun Y, ... Schipper MJ, Jolly S. Cardiac events and dose escalated radiotherapy: Combined analysis of prospective multicenter trials for locally advanced non-small cell lung cancer, J Clin Oncol (accepted): 2017. (In Press).
  • Boonstra PS, Braun TM, Taylor JMG, Kidwell K, Zhao L, Daignault SD, Griffith KA, Lawrence TS, Kalemkerian GP and Schipper MJ. Statistical Controversies In Cancer Research: Building the bridge to phase II: Efficacy estimation in dose-expansion cohorts. Ann Oncol (Accepted): 2017. (In Press).

Web Sites